An Open-Label, Multi-Center, Randomized Phase 1b/2 Study Of PF-05212384 Plus 5-Fluorouracil-Leucovorin-Irinotecan (FOLFIRI) Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Gedatolisib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
Indications Colorectal cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Pfizer

15 Oct 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
18 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
22 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com